NRXN3: A Potential Drug Target for Neurological Disorders (G9369)

Target Name: NRXN3

NCBI ID: G9369

NRXN3

NRXN3: A Potential Drug Target for Neurological Disorders

Neurexin 3 (NRXN3), also known as transcript variant 7, is a protein that is expressed in the nervous system and has been identified as a potential drug target for various neurological disorders. NRXN3 is a transmembrane protein that is composed of four intracellular domains: an N-terminal cytoplasmic domain, a transmembrane domain, an A-type cytoplasmic domain, and a C-type cytoplasmic domain.

The N-terminal cytoplasmic domain is rich in conserved hypothetical transmembrane interactions (HITMs), which are potential binding sites for small molecules. The transmembrane domain is responsible for the protein's ability to interact with the cytoplasmic domain and the extracellular matrix (ECM). A-type cytoplasmic domain is a common structural domain in proteins that interact with intracellular signaling pathways, such as the tyrosine kinase signaling pathway. The C-type cytoplasmic domain is a structural domain that is similar to the A-type cytoplasmic domain and is involved in protein-protein interactions.

NRXN3 is a protein that has been shown to play a role in various neurological disorders, including Alzheimer's disease, Parkinson's disease, and epilepsy. Studies have shown that NRXN3 is involved in the regulation of intracellular signaling pathways, including the tyrosine kinase signaling pathway, which is involved in the development and progression of these disorders.

One of the most promising aspects of NRXN3 is its potential as a drug target. Drugs that targetNRXN3 have been shown to be effective in treating these disorders. For example, a drug called NL-1138, which is a small molecule that binds to the N -terminal cytoplasmic domain of NRXN3, has been shown to be effective in animal models of Alzheimer's disease. The drug was shown to reduce the formation of beta-amyloid plaques, which are a hallmark of Alzheimer's disease, in the brain.

Another drug that targets NRXN3 is called NL-1519.This drug is a small molecule that binds to the C-type cytoplasmic domain of NRXN3.It has been shown to be effective in animal models of epilepsy.The drug has been shown to reduce the frequency of epileptic episodes in the treated animals.

NRXN3 is also a potential biomarker for various neurological disorders. Studies have shown that the levels of NRXN3 are altered in the brains of individuals with Alzheimer's disease and Parkinson's disease. The levels of NRXN3 have also been shown to be elevated in the brains of individuals with epilepsy.

In conclusion, Neurexin 3 (NRXN3) is a protein that has been identified as a potential drug target for various neurological disorders. Its ability to interact with intracellular signaling pathways and its role in the regulation of these pathways make it an attractive target for drug development .The studies that have been conducted on NRXN3 suggest that it has the potential to be a valuable tool in the treatment of these disorders. Further research is needed to fully understand the role of NRXN3 as a drug target and its potential as a biomarker for these disorders.

Protein Name: Neurexin 3

Functions: Neuronal cell surface protein that may be involved in cell recognition and cell adhesion. May mediate intracellular signaling (By similarity)

The "NRXN3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NRXN3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets